Analysis of the gene coding for the BRCA2-Interacting protein PALB2 in hereditary prostate cancer
dc.contributor.author | Tischkowitz, Marc | en_US |
dc.contributor.author | Sabbaghian, Nelly | en_US |
dc.contributor.author | Ray, Anna M. | en_US |
dc.contributor.author | Lange, Ethan M. | en_US |
dc.contributor.author | Foulkes, William D. | en_US |
dc.contributor.author | Cooney, Kathleen A. | en_US |
dc.date.accessioned | 2008-03-31T18:39:07Z | |
dc.date.available | 2009-05-04T19:09:21Z | en_US |
dc.date.issued | 2008-05-01 | en_US |
dc.identifier.citation | Tischkowitz, Marc; Sabbaghian, Nelly; Ray, Anna M.; Lange, Ethan M.; Foulkes, William D.; Cooney, Kathleen A. (2008). "Analysis of the gene coding for the BRCA2-Interacting protein PALB2 in hereditary prostate cancer." The Prostate 68(6): 675-678. <http://hdl.handle.net/2027.42/58069> | en_US |
dc.identifier.issn | 0270-4137 | en_US |
dc.identifier.issn | 1097-0045 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/58069 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=18288683&dopt=citation | |
dc.description.abstract | BACKGROUND The genetic basis of susceptibility to prostate cancer (PRCA) remains elusive. Mutations in BRCA2 have been associated with increased prostate cancer risk and account for around 2% of young onset (<56 years) prostate cancer cases. PALB2 is a recently identified breast cancer susceptibility gene whose protein is closely associated with BRCA2 and is essential for BRCA2 anchorage to nuclear structures. This functional relationship made PALB2 a candidate PRCA susceptibility gene. METHODS We sequenced PALB2 in probands from 95 PRCA families, 77 of which had two or more cases of early onset PRCA (age at diagnosis <55 years), and the remaining 18 had one case of early onset PRCA and five or more total cases of PRCA. RESULTS Two previously unreported variants, K18R and V925L were identified, neither of which is in a known PALB2 functional domain and both of which are unlikely to be pathogenic. No truncating mutations were identified. CONCLUSIONS These results indicate that deleterious PALB2 mutations are unlikely to play a significant role in hereditary prostate cancer. Prostate 68: 675–678, 2008. © 2008 Wiley-Liss, Inc. | en_US |
dc.format.extent | 82211 bytes | |
dc.format.extent | 3118 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | Wiley Subscription Services, Inc., A Wiley Company | en_US |
dc.subject.other | Life and Medical Sciences | en_US |
dc.subject.other | Cancer Research, Oncology and Pathology | en_US |
dc.title | Analysis of the gene coding for the BRCA2-Interacting protein PALB2 in hereditary prostate cancer | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Internal Medicine and Specialties | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Departments of Internal Medicine and Urology, University of Michigan, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationum | Departments of Internal Medicine and Urology, University of Michigan, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationother | Program in Cancer Genetics, Departments of Oncology, Human Genetics and Medicine, McGill University, MontrÉal, QC, Canada ; Segal Cancer Centre, Sir M. B. Davis-Jewish General Hospital, CÔte St-Catherine, MontrÉal, QC, Canada | en_US |
dc.contributor.affiliationother | Program in Cancer Genetics, Departments of Oncology, Human Genetics and Medicine, McGill University, MontrÉal, QC, Canada ; Segal Cancer Centre, Sir M. B. Davis-Jewish General Hospital, CÔte St-Catherine, MontrÉal, QC, Canada | en_US |
dc.contributor.affiliationother | Departments of Genetics and Biostatistics, University of North Carolina, Chapel Hill, North Carolina | en_US |
dc.contributor.affiliationother | Program in Cancer Genetics, Departments of Oncology, Human Genetics and Medicine, McGill University, MontrÉal, QC, Canada ; Segal Cancer Centre, Sir M. B. Davis-Jewish General Hospital, CÔte St-Catherine, MontrÉal, QC, Canada ; Research Institute, McGill University Health Centre, MontrÉal, Quebec, Canada ; Cancer Prevention Centre, Segal Cancer Centre Sir M.B. Davis Jewish General Hospital, 3755 CÔte St Catherine, MontrÉal, Quebec, Canada H3T 1E2. | en_US |
dc.identifier.pmid | 18288683 | |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/58069/1/20729_ftp.pdf | |
dc.identifier.doi | http://dx.doi.org/10.1002/pros.20729 | en_US |
dc.identifier.source | The Prostate | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.